Eletriptan

Giorgio Sandrini, Armando Perrotta, Cristina Tassorelli, Giuseppe Nappi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Migraine is a multifactorial chronic central nervous system disorder, characterized by recurrent disabling attacks of moderate-to-severe headache. Symptomatic acute treatment of migraine should provide rapid and effective relief of the headache pain. The introduction of the 5-HT1B/1D receptor agonists (triptans) expanded the armamentarium for acute migraine pain treatment. Eletriptan is a second-generation triptan with favorable bioavailability and half-life, a high affinity for 5-HT1B/1D receptors and selectivity for cranial arteries. Eletriptan (40 and 80 mg) has been shown to be effective as early as 30 min after administration and well tolerated when compared to placebo. In comparative clinical trials, eletriptan 40 and 80 mg were superior or equivalent to other triptans and have shown a very high safety and tolerability profile across the studies performed. Eletriptan showed the most favorable cost-effectiveness profile when compared with other agents in its class.

Original languageEnglish
Pages (from-to)1587-1598
Number of pages12
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume5
Issue number12
DOIs
Publication statusPublished - Dec 2009

Fingerprint

Tryptamines
Migraine Disorders
Receptor, Serotonin, 5-HT1B
Headache
Central Nervous System Diseases
Acute Pain
Neurology
Cost effectiveness
Biological Availability
Cost-Benefit Analysis
Half-Life
Arteries
Placebos
Clinical Trials
Safety
Pain
eletriptan
Therapeutics

Keywords

  • Eletriptan
  • Migraine
  • Serotonin agonists
  • Triptans

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Eletriptan. / Sandrini, Giorgio; Perrotta, Armando; Tassorelli, Cristina; Nappi, Giuseppe.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 5, No. 12, 12.2009, p. 1587-1598.

Research output: Contribution to journalArticle

Sandrini, Giorgio ; Perrotta, Armando ; Tassorelli, Cristina ; Nappi, Giuseppe. / Eletriptan. In: Expert Opinion on Drug Metabolism and Toxicology. 2009 ; Vol. 5, No. 12. pp. 1587-1598.
@article{e2ad7806109b426caa2be84afae5004d,
title = "Eletriptan",
abstract = "Migraine is a multifactorial chronic central nervous system disorder, characterized by recurrent disabling attacks of moderate-to-severe headache. Symptomatic acute treatment of migraine should provide rapid and effective relief of the headache pain. The introduction of the 5-HT1B/1D receptor agonists (triptans) expanded the armamentarium for acute migraine pain treatment. Eletriptan is a second-generation triptan with favorable bioavailability and half-life, a high affinity for 5-HT1B/1D receptors and selectivity for cranial arteries. Eletriptan (40 and 80 mg) has been shown to be effective as early as 30 min after administration and well tolerated when compared to placebo. In comparative clinical trials, eletriptan 40 and 80 mg were superior or equivalent to other triptans and have shown a very high safety and tolerability profile across the studies performed. Eletriptan showed the most favorable cost-effectiveness profile when compared with other agents in its class.",
keywords = "Eletriptan, Migraine, Serotonin agonists, Triptans",
author = "Giorgio Sandrini and Armando Perrotta and Cristina Tassorelli and Giuseppe Nappi",
year = "2009",
month = "12",
doi = "10.1517/17425250903410226",
language = "English",
volume = "5",
pages = "1587--1598",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Taylor and Francis Ltd.",
number = "12",

}

TY - JOUR

T1 - Eletriptan

AU - Sandrini, Giorgio

AU - Perrotta, Armando

AU - Tassorelli, Cristina

AU - Nappi, Giuseppe

PY - 2009/12

Y1 - 2009/12

N2 - Migraine is a multifactorial chronic central nervous system disorder, characterized by recurrent disabling attacks of moderate-to-severe headache. Symptomatic acute treatment of migraine should provide rapid and effective relief of the headache pain. The introduction of the 5-HT1B/1D receptor agonists (triptans) expanded the armamentarium for acute migraine pain treatment. Eletriptan is a second-generation triptan with favorable bioavailability and half-life, a high affinity for 5-HT1B/1D receptors and selectivity for cranial arteries. Eletriptan (40 and 80 mg) has been shown to be effective as early as 30 min after administration and well tolerated when compared to placebo. In comparative clinical trials, eletriptan 40 and 80 mg were superior or equivalent to other triptans and have shown a very high safety and tolerability profile across the studies performed. Eletriptan showed the most favorable cost-effectiveness profile when compared with other agents in its class.

AB - Migraine is a multifactorial chronic central nervous system disorder, characterized by recurrent disabling attacks of moderate-to-severe headache. Symptomatic acute treatment of migraine should provide rapid and effective relief of the headache pain. The introduction of the 5-HT1B/1D receptor agonists (triptans) expanded the armamentarium for acute migraine pain treatment. Eletriptan is a second-generation triptan with favorable bioavailability and half-life, a high affinity for 5-HT1B/1D receptors and selectivity for cranial arteries. Eletriptan (40 and 80 mg) has been shown to be effective as early as 30 min after administration and well tolerated when compared to placebo. In comparative clinical trials, eletriptan 40 and 80 mg were superior or equivalent to other triptans and have shown a very high safety and tolerability profile across the studies performed. Eletriptan showed the most favorable cost-effectiveness profile when compared with other agents in its class.

KW - Eletriptan

KW - Migraine

KW - Serotonin agonists

KW - Triptans

UR - http://www.scopus.com/inward/record.url?scp=71049154907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71049154907&partnerID=8YFLogxK

U2 - 10.1517/17425250903410226

DO - 10.1517/17425250903410226

M3 - Article

C2 - 19929447

AN - SCOPUS:71049154907

VL - 5

SP - 1587

EP - 1598

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 12

ER -